(Q46636339)

23 December 2017

title

Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease (English)

1 reference

23 December 2017

author name string

Charles S Lieber

1

1 reference

23 December 2017

David G Weiss

2

1 reference

23 December 2017

Fiorenzo Paronetto

3

1 reference

23 December 2017

Veterans Affairs Cooperative Study 391 Group

4

1 reference

23 December 2017

publication date

15 April 2008

1 reference

23 December 2017

Alcoholism: Clinical and Experimental Research

published in

1 reference

23 December 2017

volume

32

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

1031-1039

1 reference

23 December 2017

Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Evaluation of liver fibrosis: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

I. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse/physician teams

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Is serum hyaluronan a helpful tool in the management of patients with liver diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Noninvasive diagnosis of hepatic fibrosis or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Caution before embracing serum markers of liver fibrosis in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Effects of alcohol consumption on eight circulating markers of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Serum hyaluronate correlates with histological progression in alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2008.00664.X

10.1111/J.1530-0277.2008.00664.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017